Cancer Family
Stromal Neoplasm
CI-CAN-00000360Explore in graph →
Non-malignant52 active trials2 approved drugs89 evidence items
- NCIt
- C6781
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000360Explore in graph →
Clinical trials
355 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03493152 | Expanded Access to Everolimus, for an Individual Patient With GIST (Gastrointestinal Stromal Tumors)(CTMS#18-0019) | no longer available | — | — | The University of Texas Health Science Center at San AntonioOTHER | 0 | May 28, 2025 | clinicaltrials |
| NCT01689376 | Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy (Managed Access Program) | no longer available | — | — | BayerINDUSTRY | 0 |
| Aug 16, 2016 |
| clinicaltrials |
| NCT01613053 | Continuation of Drug Supply in Chinese Patients After CAMN107DBR01study Termination(MACS2226) | no longer available | — | — | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 24, 2015 | clinicaltrials |
| NCT01646593 | Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy | no longer available | — | — | BayerINDUSTRY | 0 | Dec 15, 2014 | clinicaltrials |
Data updated 22 days agoSource updated May 28, 2025source: clinicaltrials